Clinical Trial

Heart Failure With Preserved Ejection Fraction: Evaluation and Recognition by CMR

Study acronym: PREFER-CMR
Not Yet Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated January 5, 2022 (before its estimated January 2026 completion). Its status may not reflect the trial's current state.
Summary
Heart failure with preserved ejection fraction (HFpEF) is a common and growing condition with a poor prognosis but the pathophysiology and management are still being investigated. The PREFER-CMR project aims to evaluate and validate the application of novel 4D cardiac magnetic resonance flow dynamic methods to measure left ventricular pressures and validate these measurements with direct pressure measurement by coronary angiography. This is a prospective observational study of patients with HFpEF undergoing clinical evaluation with coronary angiography who will also undergo contemporaneous cardiac MRI. The primary outcome will be the level of agreement between the two methods using angiography as the reference method.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2021-11-05.
Trial Details
NCT Number NCT05114785
Lead Sponsor University of East Anglia
Collaborators: Clinical Research and Trials Unit (Norfolk & Norwich University Hospital, UK)
Conditions Heart Failure With Preserved Ejection Fraction, Heart Diseases
Enrollment 100 participants
Start Date 2022-01
Primary Completion 2026-01 (estimated)
Study Completion 2032-01 (estimated)
Updated on ClinicalTrials.gov 2022-01-05